Tudorza pressair approved for COPD

(HealthDay) -- The Tudorza Pressair (aclidinium bromide) inhaler has been approved by the U.S. Food and Drug Administration to treat narrowing of the lung airways associated with chronic obstructive pulmonary disease (COPD) in people 18 and older.

COPD, most often caused by smoking, encompasses chronic bronchitis and emphysema. Symptoms usually include , excessive phlegm and chest tightness, the FDA said in a news release.

The Tudorza Pressair inhaler, to be used twice daily, relaxes muscles around the lung's large airways, improving breathing. It is not meant to be used as a rescue inhaler during sudden asthma attacks, the agency said.

Common side effects observed during clinical testing included headache, nasal inflammation and cough.

The inhaler is distributed by St. Louis-based Forest Pharmaceuticals, a subsidiary of Forest Laboratories.


Explore further

Researchers question safety of mist inhalers for delivering common drug for chronic lung disease

More information: Medline Plus has details about COPD.

Copyright © 2012 HealthDay. All rights reserved.

Citation: Tudorza pressair approved for COPD (2012, July 24) retrieved 16 October 2019 from https://medicalxpress.com/news/2012-07-tudorza-pressair-copd.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more